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Impaired monocyte cytokine production in critically ill patients
with acute renal failure.
Background. Plasma levels of pro- and anti-inflammatory cy-
tokines are predictive of mortality in patients with acute renal
failure (ARF). Anti-inflammatory strategies are postulated to
be beneficial in treatment. However, there are few studies simul-
taneously examining monocyte cytokine production and plasma
cytokine levels in patients with ARF.
Methods. Study populations consisted of 20 critically ill pa-
tients with ARF, 19 critically ill patients without ARF (CRIT
ILL), 28 healthy subjects (HS), 19 patients with chronic kid-
ney disease (CKD), and 15 patients with end-stage renal dis-
ease (ESRD). Monocyte intracellular content of interleukin-1b
(IL-1b), interleukin-6 (IL-6), interleukin-8, and tumor necrosis
factor-a (TNF-a) was determined by flow cytometry in whole
blood. Plasma interleukin 6 and TNF-a concentrations were
determined by enzyme-linked immunosorbent assay (ELISA).
Results. At baseline, there were no differences in intracellular
monocyte cytokine levels between groups. After lipopolysac-
caride stimulation, monocyte production of IL-1b , TNF-a, and
IL-6 in ARF patients was reduced by 41%, 84%, and 45%, re-
spectively, compared to healthy subjects (P < 0.01 in each case),
and similarly reduced compared to CKD and ESRD patients,
and were similar to CRIT ILL patients. Plasma IL-6 levels were
significantly higher in ARF patients than healthy subjects, CKD,
and ESRD patients (all P < 0.001).
Conclusion. Critically ill patients with acute renal failure have
impaired monocyte cytokine production and elevated plasma
cytokine levels in a pattern that closely resembles critically ill
patients without ARF, and that is dissimilar to CKD and ESRD
patients.
Acute renal failure (ARF) is a syndrome characterized
by a rapid decline in glomerular filtration leading to the
development of azotemia and the retention of uremic so-
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lute. Unfortunately, despite many advances in medical
care over the past several decades, the mortality asso-
ciated with the development of acute renal failure re-
mains high [1–3]. For patients who develop acute renal
failure while in the hospital setting, mortality has been
reported to be between 25% and 80% [4–7]. To date, no
specific therapies have been shown to lessen the sever-
ity of established acute renal failure, or to improve the
mortality for patients with established acute renal fail-
ure [3]. Furthermore, several therapeutic strategies that
have been highly efficacious in animal models have not
been proven effective in hospitalized patients with acute
renal failure. Therapeutic strategies effective in animal
models of acute renal failure may even cause harm when
applied to human subjects with a complex disease pro-
cess [8, 9]. In animal models of acute renal failure, renal
injury is rarely accompanied by the multiorgan dysfunc-
tion syndrome frequently found in critically ill patients
with acute renal failure. Thus, conclusions derived from
animal models need to be carefully analyzed before being
employed in human clinical trials.
The Program to Improve Care in Acute Renal Disease
(PICARD) Group was developed to better understand
the natural history of acute renal failure in critically ill pa-
tients, and to explore clinical characteristics and practice
patterns associated with favorable and adverse outcomes,
including mortality and recovery of renal function. The
goal of the PICARD Group is to develop hypotheses that
can be tested in clinical trials. As part of the PICARD
Network, we have recently demonstrated that plasma cy-
tokine levels are elevated and predict mortality in criti-
cally ill patients with acute renal failure. However, levels
of both IL-6, a proinflammatory cytokine, and IL-10, and
anti-inflammatory cytokine, predict mortality, suggesting
that cytokine biology is complex in these patients [10].
However, the understanding of cytokine biology in dis-
ease states similar to ARF is often complex due to a lack
of correlation between plasma levels of cytokines and
their bioactivity [11, 12]. This interpretation is even more
difficult in the setting of renal failure, where there may
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Table 1. Demographics
Healthy subjects Acute renal failure Critically ill Chronic kidney disease End-stage renal disease
Age 45.8 ± 1.4 70.3 ± 2.9 60.5 ± 0.8 68.1 ± 3.2 49.9 ± 2.0
Gender (% male) 52 55 53 68 47
Race (% Caucasian) 93 100 100 100 100
be diminished renal clearance of cytokines. In the present
study, we sought to further advance the understanding of
cytokine biology in critically ill patients with acute renal
failure by simultaneously examining monocyte cytokine
production and plasma cytokine levels.
Measuring the capacity for ex vivo cytokine produc-
tion by blood and tissue cells may provide more com-
prehensive information regarding cytokine networks and
improve the clinical utility of cytokine measurements [13,
14]. For example, in acute lung injury, measurement of
proinflammatory cytokines in bronchial alveolar lavage
fluid provides better prognostic value than plasma cy-
tokine measurements [15–20]. In patients with urinary
tract infection, the measurement of urinary interleukin-
6 levels reflects disease severity better than circulating
interleukin-6 levels [21]. In critical illness, hyporespon-
sive monocyte inflammatory cytokine production and
increased anti-inflammatory cytokine production have
been observed to predict subsequent mortality [22–26].
In an attempt to further understand the cytokine bi-
ology, we have evaluated monocyte cytokine synthetic
capacity following LPS stimulation in a cohort of criti-
cally ill patients with ARF. The results were compared
to healthy subjects, patients with chronic kidney disease
(CKD), patients with end-stage renal disease (ESRD),
and critically ill patients without renal failure. We deter-
mined that at the time that nephrologists were asked to
participate in the care of critically ill patients with acute
renal failure, patients already had evidence of dimin-
ished ability to synthesize the proinflammatory cytokines
TNF-a, interleukin-6, and interleukin-1b in comparison
to healthy subjects, patients with CKD, and ESRD pa-
tients. Furthermore, this pattern of monocyte cytokine
hyporesponsiveness is not significantly different than is
observed in other critically ill patients without acute re-
nal failure.
METHODS
Study cohort
This study was performed as a part of the Program to
Improve Care in Acute Renal Disease (PICARD) Study.
PICARD is a prospective observational cohort study ex-
amining the natural history, practice patterns, and out-
comes of treatment in critically ill patients with ARF,
conducted at five academic medical centers in the United
States. The study period was from February 1, 1999 to
August 31, 2001. All adult (age >18 years) ICU patients
with ARF in whom a nephrology service consultation was
Table 2. Severity of illness scores
ARF Critically ill
Mean + SEM Range Mean + SEM Range P value
APACHE II 26.3 ± 1.4 10–35 16.0 ± 0.4 1–28 0.001
APACHE III 67.3 ± 4.0 25–103 41.2 ± 1.0 11–99 0.001
SAPS 43.3 ± 3.1 22–81 42.7 ± 0.6 22–63 0.87
SOFA Score 7.9 ± 0.8 2–15 5.8 ± 0.1 1–12 0.05
received were considered for the study. Acute renal fail-
ure was defined using standard laboratory parameters.
For patients with no prior history of kidney disease or
baseline creatinine values of <1.5 mg/dL, ARF was de-
fined by a sustained increase in serum creatinine of at least
0.5 mg/dL. For those patients with preexisting chronic re-
nal insufficiency (baseline creatinine values >1.5 mg/dL),
ARF was defined by a sustained rise in serum creatinine
of >1 mg/dL from baseline. Exclusion criteria included
previous dialysis, kidney transplantation, ARF from uri-
nary tract obstruction, and hypovolemia responsive to
fluids, as well as prisoners and pregnant patients. The
characteristics of the PICARD population, as well as
the inclusion and exclusion criteria have been published
elsewhere [27]. The study was approved by the Institu-
tional Review Board of each participating hospital, and
informed consent was obtained from all study partici-
pants or their next of kin.
For this substudy, a cohort of 20 patients meeting
PICARD inclusion criteria at the Maine Medical Cen-
ter was asked to undergo intracellular and plasma cy-
tokine measurements. All patients were studied within
48 hours of initial nephrology consultation. Baseline clin-
ical characteristics for these patients are presented in
Table 1. For comparison to the cohort of critically ill pa-
tients with acute renal failure, 19 critically ill patients
without ARF, 19 patients with chronic kidney disease
(GFR mean 31 ± 2 mL/min, range 15–47 mL/min), and 15
patients with ESRD were studied. Twenty-eight healthy
subjects were also studied for comparison. For ARF and
critically ill patients, the Simplified Acute Physiology
Score (SAPS) II and Sequential Organ System Failure
(SOFA) score was determined as previously described
[28, 29]. Sepsis was defined by ACCP/SCCM Guidelines
(Table 2) [30].
Measurements of monocyte intracellular
cytokine content
Intracellular cytokines were measured by the FastIm-
mune Cytokine System (Becton Dickinson, San Jose, CA,
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USA). This assay system measures total cellular cytokine
synthetic activity after inhibition of cytokine exocytosis
(e.g., secretion) and stimulation with lipopolysaccharide
(LPS). This methodology is advantageous compared to
methodologies that focus on cytokine mRNA because
there can be discordance between cytokine transcription
and translation [31–33]. This method has the additional
advantage that intracellular cytokine expression is un-
affected by the release of cytokine inhibitors during an
inflammatory response [34–36]. Briefly, whole blood is
collected into Vacutainer tubes containing sodium hep-
arin and incubated with and without 1 lg/mL LPS in the
presence of Brefeldin A (BFA), and is further incubated
for four hours at 37◦C, 5% CO2. BFA is added to inhibit
intracellular transport and prevent cytokine exocytosis.
After incubation, 50 lL aliquots of blood are added to
polystyrene tubes that contain 20 lL of antihuman CD33
phycoerythrin-conjugated antibody and incubated for
15 minutes at room temperature in the dark. To lyse red
cells and fix white cells, 2 mL of FACS Lysing Solution
(Becton Dickinson) are added to each tube, incubated
for 10 minutes at room temperature in the dark, and then
centrifuged at 500g for five minutes; the supernatant is
then removed. Subsequently, 500 lL of FACS Perme-
abilizing Solution (Becton Dickinson, San Jose, CA) are
added into each tube and incubated for 10 minutes at
room temperature in the dark. The cells are washed with
2 mL of buffer and centrifuged at 500g for five min-
utes, followed by the removal of the supernatant. Intra-
cellular cytokines are stained by the addition of 20 lL
cytokine antigen-specific fluorescein isothiocyanate con-
jugated monoclonal antibodies and incubated for 30 min-
utes at room temperature in the dark. Thereafter, the cells
are washed with 2 mL of washing buffer and resuspended
in 400 lL of 1% paraformaldehyde before cells are ana-
lyzed on a FACScan (Becton Dickinson, Mountainview,
CA). Antibodies to IL-1b , TNF-a, IL-8, and IL-6 were
chosen to reflect proinflammatory cytokines known to be
produced by activated phagocytic cells.
Plasma cytokine determination
Plasma interleukin-6 and TNF-a concentrations
were determined by enzyme-linked immunosorbent as-
say (ELISA) with kits from BioSource International
(Camarillo, CA, USA). Plasma cytokines of patient
groups were compared to a healthy subject pool used to
establish the normal range of the assays. The detectable
limits and interassay coefficients of variation for the cy-
tokines were 2.0 pg/mL and 6% for IL-6, and 3.0 pg/mL
and 10% for TNF-a, respectively.
Statistical analysis
The main outcomes followed in this study were the in-
tracellular cyokine levels. Comparisons of onetime data
among the five different study groups were completed
by using a one-way analysis of variance for normally dis-
tributed variables and the Kruskall-Wallis H test for non-
normally distributed variables. Once it was determined
that differences existed among the means, the Bonferroni
post-hoc range test was used to determine which means
were different. Separate additional comparisons between
each study group were completed by the Student t test or
the Mann-Whitney U test, using the Bonferroni test to
adjust the observed significance level to the fact that mul-
tiple comparisons were made. All tests were two-tailed,
and a significance level of 0.05 was accepted to indicate
statistical significance. All data are expressed as mean ±
SEM, unless otherwise noted. The SPSS statistical soft-
ware program (version 11.5, SPSS, Chicago, IL, USA)
was be used for all analyses.
RESULTS
Monocyte intracellular cytokine generation
Prior to administration of LPS, there were no dif-
ferences in levels of any of the monocyte intracellular
cytokines (data not shown). However, after LPS stim-
ulation, significant differences were observed. Figure 1
displays representative scattergrams obtained with this
assay, in this case comparing the LPS effect on TNF-a
synthesis. Figures 2 to 5 display the change in monocyte
intracellular cytokine content after stimulation with LPS
for the proinflammatory cytokines interleukin-1b , TNF-
a, interleukin-8, and interleukin-6. Monocyte production
of interleukin-1b , TNF-a, and interleukin-6 in ARF pa-
tients was reduced by 41%, 84%, and 45%, respectively,
compared to healthy subjects (P < 0.01 in each case). Sim-
ilarly, monocyte interleukin-1b , TNF-a, and interleukin-
6 production in acute renal failure patients was reduced
by 36%, 82%, and 53%, respectively, compared to pa-
tients with chronic kidney disease (P < 0.01 in each case),
and 44%, 79%, and 63%, respectively, compared to pa-
tients with ESRD (P < 0.01 in each case). There was
a similar reduction of stimulated monocyte production
of interleukin-1b , TNFa, and interleukin-6 in critically
ill patients without ARF that did not differ significantly
from ARF patients. There were no significant differences
in monocyte intracellular interleukin-8 production be-
tween any of the patient groups.
Plasma proinflammatory cytokine levels
Figure 6 demonstrates the plasma cytokine content
of plasma obtained at the same time as the intracellu-
lar monocyte cytokine assays. Plasma interleukin-6 lev-
els were markedly elevated in critically ill patients with
acute renal failure (163.3 ± 24.9 pg/mL) compared to
healthy subjects (2.91 ± 0.6 pg/mL, P < 0.001), patients
with chronic kidney disease (8.7 ± 1.7 pg/mL, P < 0.001),
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Fig. 1. Monocyte tumor necrosis factor-a
(TNF-a) synthesis measured by flow cytom-
etry. Monocyte TNF-a content is measured
on the Y-axis. Representative healthy sub-
ject without LPS stimulation (A), healthy sub-
ject after LPS stimulation (B), representative
acute renal failure patient without LPS stim-
ulation (C), acute renal failure patient after
LPS stimulation (D).
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Fig. 2. Monocyte interleukin-1b content. ∗P ≤ 0.001 vs. healthy sub-
jects.
and ESRD patients (21.3 ± 5.4 pg/mL, P < 0.001). Plasma
interleukin-6 levels were similarly elevated in critically ill
patients without acute renal failure (280.1 ± 72.8 pg/mL,
P = 0.14) as in ARF patients. Plasma levels of TNF-a
were also significantly elevated in critically ill patients
with acute renal failure (45.6 ± 3.7 pg/mL) compared to
healthy subjects (10.6 ± 1.0 pg/mL, P < 0.00001). Pa-
tients with chronic kidney disease also had significantly
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Fig. 3. Monocyte TNF-a content. ∗P < 0.001 vs. healthy subjects.
elevated plasma TNF-a levels compared to healthy sub-
jects (37.1 ± 2.9 pg/mL, P < 0.00001), which did not
significantly differ from ARF patients. Similarly, plasma
TNF-a levels in ESRD patients (44.7 ± 4.0 pg/mL) and
critically ill patients without acute renal failure (22.8 ±
3.2 pg/mL) were significantly different from healthy sub-
jects, but did not differ from ARF patients.
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Fig. 4. Monocyte interleukin-8 content.
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Fig. 5. Monocyte IL-6 content. ∗P ≤ 0.02 vs. healthy subjects.
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Fig. 6. Plasma IL-6 and TNF-a levels. ∗P ≤ 0.01 vs. healthy subjects;
#P ≤ 0.001 vs. ARF patients.
DISCUSSION
In critically ill patients, proinflammatory cytokines are
often considered as the engine that drives the systemic
inflammatory response [37]. Inflammatory stimuli result-
ing from tissue injury or exposure to infectious agents
cause the release of interleukin-1, interleukin-6, and tu-
mor necrosis factor-a from phagocytic cells. The result-
ing overwhelming cytokine release can lead to develop-
ment of the systemic inflammatory response syndrome
(SIRS) and contribute to the development of multiple
organ system failure [38, 39]. In animal models, the exag-
gerated production of TNF-a and other proinflammatory
cytokines also plays a prominent role in the subsequent
development of acute renal failure after renal ischemia
and nephrotoxic exposure [40]. Further evidence sug-
gests that transmigration of leukocytes into areas of renal
injury, promoted by the increased expression of intra-
cellular adhesion molecule-1 (ICAM-1) on activated en-
dothelial cells, may contribute to renal injury in ischemic
and toxic animal models of acute renal failure [41–43].
These observations, derived from animal models, have led
to the suggestion that anti-inflammatory strategies may
be clinically useful in diminishing the extent of nephro-
toxic or ischemic renal injury and accelerating recovery
after nephrotoxic or ischemic injury has taken place.
In our earlier study, levels of plasma IL-6 and
the prototypical anti-inflammatory cytokine IL-10 were
each found to differ between subsequent survivors and
nonsurvivors [10]. Interleukin-10 counter-regulates the
cascade of proinflammatory cytokines that develop as
a result of tissue injury [44]. In the sepsis syndrome,
elevated plasma IL-10 levels have also previously been
associated with poor survival [22–26]. Furthermore,
interleukin-10 can directly inhibit the monocyte inflam-
matory response to endotoxin, thereby leading to mono-
cyte hyporesponsiveness, as was observed in the present
study. Monocyte hyporesponsiveness, likely as a result
of an increase in IL-10 and other anti-inflammatory cy-
tokines, has been independently associated with mor-
tality in critically ill patients with sepsis. This increase
in IL-10 and other anti-inflammatory cytokines after an
acute-phase inflammatory response has been termed the
“counter anti-inflammatory syndrome,” or CARS [45].
The results of the present study further extend the find-
ings in our previous study that derangements of cytokine
biology in ARF patients are complex, and more closely
resemble derangements observed in critically ill patients
without acute renal failure than patients with chronic
kidney disease. Taken collectively, these two studies sug-
gest that critically ill patients with established acute re-
nal failure often undergo simultaneous SIRS and CARS,
rather than experiencing CARS temporally dissociated
from and after SIRS. This severely dysregulated aspect
of cytokine biology would explain the apparent discor-
dance between high plasma proinflammatory cytokine
levels and simultaneously low monocyte cytokine respon-
siveness.
The importance of distinguishing between plasma cy-
tokine levels and cellular cytokine generational capacity
is perhaps best exemplified by examining TNF-a biology
in patients with sepsis syndrome. TNF-a is a key factor in
the development of sepsis, and high serum TNF-a levels
are observed within one to two hours after endotoxin ad-
ministration to animals [46]. Administration of recombi-
nant TNF-a produces clinical manifestations very similar
to septic shock, while other studies have demonstrated
that pretreatment with anti-TNF antibodies protects an-
imals from endotoxin challenge. However, while some
clinical studies have documented a correlation between
blood TNF-a levels and poor prognosis in sepsis, these
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findings have been highly variable [47, 48]. Furthermore,
a number of recent studies have demonstrated that TNF-
a synthesis stimulated by endotoxin ex vivo is consider-
ably suppressed in septic patients compared to healthy
volunteers, even while plasma TNF-a levels are still el-
evated [24, 25, 49–52]. Suppression of ex vivo TNF-a
synthesis has additionally directly been correlated with
higher mortality in septic patients [26]. Most important,
more than 10 large phase III trials designed to inhibit
the biologic effect of TNF-a in septic patients, using ei-
ther neutralizing monoclonal anti-TNF-a antibodies or
soluble TNF receptor fusion proteins, failed to achieve
a survival benefit [26]. These studies are similar to the
findings in the present study in ARF patients, point to
the complexity of cytokine networks in critical illness,
and emphasize the importance of examining cellular cy-
tokine synthetic capability in addition to plasma cytokine
levels.
To date there have been remarkably few clinical studies
examining monocyte cytokine production in patients with
acute renal failure. Jaber et al [53] examined the effect of
dialyzer membrane type on cytokine synthesis by periph-
eral blood mononuclear cells in patients with acute renal
failure without comparison to other patient populations.
Lonnemann et al examined ex vivo endotoxin-induced
production of TNF-a in PBMCs isolated from patients
with acute renal failure receiving renal replacement ther-
apy and demonstrated marked reduction in TNF-a syn-
thetic capacity compared to healthy subjects, similar to
the present study [54]. The results of the present study
use a whole blood assay to extend the findings of Lonne-
mann et al by demonstrating that the anti-inflammatory
response begins earlier in the course of renal failure than
previously recognized, and by examining a larger panel
of proinflammatory cytokines.
A limitation of the present study is that only patients
who met PICARD entry criteria and, thus, were criti-
cally ill with established acute renal failure and referred
for nephrology consultation were studied. We chose to
study this patient population because of their known high
mortality and the lack of available effective therapies.
We did not examine cytokine biology in less severely ill
patients with acute renal failure. Further studies of cy-
tokine biology employing plasma and urinary markers
of early renal tubular injury may facilitate an increased
understanding of the extent to which proinflammatory cy-
tokines contribute to the development of acute renal fail-
ure [55–57]. These studies would provide new and highly
valuable additional information. Examination of other
aspects of monocyte activation, including assays measur-
ing transcription factor activation, degranulation, urinary
cytokine levels, and other assays not employed in the
present study would also facilitate an increased under-
standing of the role of inflammation in patients with acute
renal failure.
CONCLUSION
Critically ill patients with acute renal failure display
evidence of impaired proinflammatory monocyte cy-
tokine production in a cohort of patients at the time of
nephrology consultation. This impairment of monocyte
cytokine production occurs contemporaneously with ele-
vated plasma levels of proinflammatory cytokines. These
findings suggest that strategies designed to reduce inflam-
mation in critically ill patients with already established
acute renal failure in an effort to accelerate renal func-
tional recovery should be attempted with caution so as
not to exacerbate the already high risk of infectious com-
plications in this patient population.
ACKNOWLEDGMENTS
We gratefully acknowledge the administrative assistance of Karen
A. Kinne in the preparation of this manuscript. We also acknowledge
the support of the members of the PICARD Study Group: Cleve-
land Clinic Foundation, Cleveland, OH: Emil Paganini, M.D., Tracy
Seifert, RN, Michelle Garcia, RN, Lydia Sweeney, RN; Maine Medical
Center, Portland, ME: Jonathan Himmelfarb, M.D., Stephanie Freed-
man, RN, Rebecca Violette; UCSD Medical Center, San Diego, CA—
Ravindra Mehta, M.D., Maria T. Pascual, RN, Carmencita Gruta, RN;
UCSF Medical Center, San Francisco, CA: Glenn Chertow M.D., Susan
Robertson, RN; Vanderbilt Medical Center, Nashville, TN: T. Alp Iki-
zler, M.D., Cathi Martin, RD, Clare Burson; Data Coordinating Center,
San Diego, CA: Ravindra Mehta, M.D., Brandon Savage, M.D., Sharon
Soroko, MS; Consultants: Tom Greene, Ph.D., Brett Larive, Ph.D.
Reprint requests to Jonathan Himmelfarb, M.D., Director, Division
of Nephrology and Renal Transplantation, Maine Medical Center, 22
Bramhall Street, Portland, ME 04102.
E-mail: himmej@mmc.org
REFERENCES
1. THADHANI R, PASCUAL M, BONVENTRE JV: Acute renal failure. N
Engl J Med 334:1448–1460, 1996
2. LIANO F, PASCUAL J: Outcomes in acute renal failure. Semin Nephrol
18:541–550, 1998
3. STAR RA: Treatment of acute renal failure. Kidney Int 54:1817–1831,
1998
4. LIANO F, JUNCO E, PASCUAL J, et al: The spectrum of acute renal
failure in the intensive care unit compared with that seen in other
settings. The Madrid Acute Renal Failure Study Group. Kidney Int
(Suppl 66):S16–S24, 1998
5. MEHTA RL, MCDONALD B, GABBAI FB, et al: A randomized clinical
trial of continuous versus intermittent dialysis for acute renal failure.
Kidney Int 60:1154–1163, 2001
6. NASH K, HAFEEZ A, HOU S: Hospital-acquired renal insufficiency.
Am J Kidney Dis 39:930–936, 2002
7. SCHIFFL H, LANG SM, FISCHER R: Daily hemodialysis and the out-
come of acute renal failure. N Engl J Med 346:305–310, 2002
8. ACKER CG, SINGH AR, FLICK RP, et al: A trial of thyroxine in acute
renal failure. Kidney Int 57:293–298, 2000
9. WANG A, HOLCSLAW T, BASHORE TM, et al: Exacerbation of radio-
contrast nephrotoxicity by endothelin receptor antagonism. Kidney
Int 57:1675–1680, 2000
10. SIMMONS EM, HIMMELFARB J, SEZER MT, et al: Plasma cytokine levels
predict mortality in patients with acute renal failure. Kidney Int
65:1357–1365, 2004
11. ALLISON AC, LEE JC, EUGUI EM: Pharmacological regulation of the
production of inflammatory cytokines TNF-a and IL-1-b , in Human
Cytokines: Their Role in Disease and Therapy, edited by Aggarwal
B, Puri RK, Boston, Blackwell Science, 1995, pp 689–713
12. MAINO VC, PICKER LJ: Identification of functional subsets by flow
2360 Himmelfarb et al: Intracellular cytokines in ARF
cytometry: Intracellular detection of cytokine expression. Cytome-
try 34:207–215, 1998
13. BIENVENU J, MONNERET G, FABIEN N, REVILLARD JP: The clinical
usefulness of the measurement of cytokines. Clin Chem Lab Med
38:267–285, 2000
14. DELARCHE C, CHOLLET-MARTIN S: Plasma cytokines: What we are
measuring. Current Opinion in Clinical Nutrition and Metabolic
Care 2:475–479, 1999
15. PUGIN J, RICOU B, STEINBERG KP, et al: Proinflammatory activity in
bronchoalveolar lavage fluids from patients with ARDS, a promi-
nent role for interleukin-1. Am Respir Care Med 153:1850–1856,
1996
16. GRENIER A, DEHOUX M, BOUTTEN A, et al: Oncostatin M production
and regulation by human polymorphonuclear neutrophils. Blood
93:1413–1421, 1999
17. CHOLLET-MARTIN S, MONTRAVERS P, GILBERT C, et al: High levels
of interleukin-8 in the blood and alveolar spaces of patients with
pneumonia and adult respiratory distress syndrome. Infect Immun
61:4553–4559, 1993
18. MEDURI GU, KOHLER G, HEADLEY S, et al: Inflammatory cytokines
in the BAL of patients with ARDS. Chest 108:1303–1314, 1995
19. DONNELLY SC, STREITER RM, REID PT, et al: The association be-
tween mortality rates and decreased concentrations of interleukin-
10 and interleukin-1 receptor antagonist in the lung fluids of pa-
tients with the adult respiratory distress syndrome. Ann Intern Med
125:191–196, 1996
20. PITTET JF, MACKERSIE RC, MARTIN TR, et al: Biological markers of
acute lung injury: Prognostic and pathogenetic significance. Am J
Respir Crit Care Med 155:1187–1205, 1997
21. OTTO G, BRACONIER JA, ANDREASSON A, SVANBORG C: Interleukin-6
and disease severity in patients with bacteremic and nonbacteremic
febrile urinary tract infection. J Intern Med 179:172–179, 1999
22. ERTEL W, KREMER JP, KENNEY J, et al: Downregulation of proin-
flammatory cytokine release in whole blood from septic patients.
Blood 85:1341–1347, 1995
23. GOGOS CA, DROSOU E, BASSARIS HP, SKOUTELIS A: Pro- versus
anti-inflammatory cytokine profile in patients with severe sepsis:
A marker for prognosis and future therapeutic options. J Infect Dis
181:176–180, 2000
24. VAN DISSEL JT, VAN LANGEVELDE P, WESTENDORP RG, et al: Anti-
inflammatory cytokine profile and mortality in febrile patients.
Lancet 351:950–953, 1998
25. ASTIZ M, SAHA D, LUSTBADER D, et al: Monocyte response to bacte-
rial toxins, expression of cell surface receptors, and release of anti-
inflammatory cytokines during sepsis. J Lab Clin Med 128:594–600,
1996
26. MUNOZ C, CARLET J, FITTING C, et al: Dysregulation of in vitro cy-
tokine production by monocytes during sepsis. J Clin Invest 88:1747–
1754, 1991
27. CHERTOW GM, PASCUAL MT, SOROKO S, et al: Reasons for non-
enrollment in a cohort study of ARF: The Program to Improve Care
in Acute Renal Disease (PICARD) experience and implications for
a clinical trials network. Am J Kidney Dis 42:507–512, 2003
28. LE GALL JR, LEMESHOW S, SAULNIER F: A new Simplified Acute
Physiology Score (SAPS II) based on a European/North American
multicenter study. JAMA 270:2957–2963, 1993
29. VINCENT JL, MORENO R, TAKALA J, et al: The SOFA (Sepsis-
related Organ Failure Assessment) score to describe organ dysfunc-
tion/failure. On behalf of the Working Group on Sepsis-Related
Problems of the European Society of Intensive Care Medicine. In-
tensive Care Med 22:707–710, 1996
30. BONE RC, BALK RA, CERRA FB, et al: Definitions for sepsis and or-
gan failure and guidelines for the use of innovative therapies in sep-
sis. The ACCP/SCCM Consensus Conference Committee. Ameri-
can College of Chest Physicians/Society of Critical Care Medicine.
Chest 101:1644–1655, 1992
31. SCHINDLER R, GELFAND JA, DINARELLO CA: Recombinant C5a stim-
ulates transcription rather than translation of interleukin-1 (IL-
1) and tumor necrosis factor: Translational signal provided by
lipopolysaccharide or IL-1 itself. Blood 76:1631–1638, 1990
32. SCHINDLER R, LONNEMANN G, SHALDON S, et al: Transcription, not
synthesis, of interleukin-1 and tumor necrosis factor by complement.
Kidney Int 37:85–93, 1990
33. DINARELLO CA: Cytokines: Agents provocateurs in hemodialysis.
Kidney Int 41:683–694, 1992
34. HART PH, COOPER RL, FINLAY-JONES JJ: IL-4 suppresses IL-
1 beta, TNF-alpha and PGE2 production by human peritoneal
macrophages. Immunology 72:344–349, 1991
35. PORTEU F, NATHAN C: Shedding of tumor necrosis factor receptors
by activated human neutrophils. J Exp Med 172:599–607, 1990
36. SPINAS GA, KELLER U, BROCKHAUS M: Release of soluble recep-
tors for tumor necrosis factor (TNF) in relation to circulating TNF
during experimental endotoxinemia. J Clin Invest 90:533–536, 1992
37. DINARELLO CA: Proinflammatory cytokines. Chest 118:503–508,
2000
38. PARRILLO JE, PARKER MM, NATANSON C, et al: Septic shock in hu-
mans, advances in the understanding of pathogenesis, cardiovascu-
lar dysfunction, and therapy. Ann Int Med 113:227–240, 1990
39. PINSKY MR, VINCENT JL, DEVIERE J, et al: Serum cytokine levels in
human septic shock: Relation to mutliple-system organ dysfunction
and mortality. Chest 103:565–575, 1999
40. DONNAHOO KK, MENG XZ, AYALA A, et al: Early kidney TNF-a
expression mediates neutrophil infiltration and injury after renal
ischemia-reperfusion. Am J Physiol (Regul Integr Comp Physiol)
277:R922–R929, 1999
41. KELLY KJ, MEEHAN SM, COLVIN RB, et al: Protection from toxicant-
mediated renal injury in the rat with anti-CD54 antibody. Kidney
Int 12:922–931, 1999
42. KELLY KJ, WILLIAMS WW JR., COLVIN RB, et al: Antibody to inter-
cellular adhesion molecule 1 protects the kidney against ischemic
injury. PNAS USA 91:812–816, 1994
43. RABB H, MENDIOLA CC, SABA SR, et al: Antibodies to ICAM-1 pro-
tect kidneys in severe ischemic reperfusion injury. Biochem Biophys
Res Commun 211:67–73, 1995
44. SFEIR T, SAHA DC, ASTIZ M, RACKOW EC: Role of interleukin-10
in monocyte hyporesponsiveness associated with septic shock. Crit
Care Med 29:129–133, 2001
45. BONE RC, GRODZIN CJ, BALK RA: Sepsis: A new hypothesis for
pathogenesis of the disease process. Chest 112:235–243, 1997
46. BEUTLER B, GRAU GE: Tumor necrosis factor in the pathogenesis
of infectious disease. Crit Care Med 21:S423–S435, 1993
47. LEROUX-ROELS G, OFFNER F: Tumor necrosis factor in sepsis. J Am
Med Assoc 263:1494–1495, 1989
48. CALANDRA T, BAUMGARTNER JD, GRAU GE, et al: Prognostic values
of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha,
and interferon-gamma in the serum of patients with septic shock.
Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 161:982–
987, 1990
49. VAN DISSEL JT, VAN LANGEVELD P, WESTENDORP RGJ, et al: Anti-
inflammatory cytokine profile and mortality in febrile patients.
Lancet 351:950–953, 1998
50. DOCKE WD, RANDOW F, SYRBE U, et al: Monocyte deactivation in
septic patients: Restoration by IFN-c treatment. Nat Med 3:678–681,
1997
51. FLACH R, MAJETSCHAK M, HEUKAMP T, et al: Relation of ex vivo stim-
ulated blood cytokine synthesis to post-traumatic sepsis. Cytokine
11:173–178, 1999
52. MARIE C, MURET J, FITTING C, et al: Reduced ex vivo interleukin-8
production by neutrophils in septic and nonseptic systemic inflam-
matory response syndrome. Blood 91:3439–3446, 1998
53. JABER BL, CENDOROGLO M, BALAKRISHNAN VS, et al: Impact of dia-
lyzer membrane selection on cellular responses in acute renal fail-
ure: A crossover study. Kidney Int 57:2107–2116, 2000
54. LONNEMANN G, BECHSTEIN M, LINNENWEBER S, et al: Tumor necrosis
factor-alpha during continuous high-flux hemodialysis in sepsis with
acute renal failure. Kidney Int 72(Suppl):S84–S87, 1999
55. MURAMATSU Y, TSUJIE M, KOHDA Y, et al: Early detection of cysteine
rich protein 61 (CYR61, CCN1) in urine following renal ischemic
reperfusion injury. Kidney Int 62:1601–1610, 2002
56. MELNIKOV VY, FAUBEL S, SIEGMUND B, et al: Neutrophil-
independent mechanisms of caspase-1- and IL-18-mediated is-
chemic acute tubular necrosis in mice. J Clin Invest 110:1083–1091,
2002
57. HAN WK, BAILLY V, ABICHANDANI R, et al: Kidney injury molecule-
1 (KIM-1): A novel biomarker for human renal proximal tubule
injury. Kidney Int 62:237–244, 2002
